CLDN5 and COVID-19: This approach identified autoantibodies targeting cardiolipin, platelet glycoprotein, and claudin 5 as the three most essential autoantibodies classifying severe COVID-19 patients <50 and ≥50 years old when compared with healthy controls at these ages (Fig. 5a, b).